Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, Spriewald B, Hanoun M, Martin S, Schwab K, Knaden J, Reiser L, Marx J, Wethmar K, Sauer T, Berdel WE, Lenz G, Brueggemann M, Raffel S, Goekbuget N (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Conference Proceedings Title: BLOOD

Event location: New Orleans, LA

DOI: 10.1182/blood-2022-162235

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Freiburg Germany (DE) Westfälische Wilhelms-Universität (WWU) Münster Germany (DE) Universitätsklinikum Münster Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Universitätsklinikum Jena Germany (DE) Universitätsklinikum Düsseldorf Germany (DE) Universitätsklinikum Augsburg Germany (DE) Klinikum Chemnitz Germany (DE) Universitätsklinikum Essen Germany (DE) Robert-Bosch-Krankenhaus Germany (DE) Rheinische Friedrich-Wilhelms-Universität Bonn Germany (DE) Goethe-Universität Frankfurt am Main Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Universitätsklinikum Heidelberg Germany (DE)

How to cite

APA:

Stelljes, M., Alakel, N., Waesch, R., Scholl, S., Nachtkamp, K., Rank, A.,... Goekbuget, N. (2022). Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial). In BLOOD. New Orleans, LA: WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Stelljes, Matthias, et al. "Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)." Proceedings of the 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA WASHINGTON: AMER SOC HEMATOLOGY, 2022.

BibTeX: Download